TOKYO, June 27,
2024 /PRNewswire/ -- Dioseve Inc. (Headquarters:
Tokyo; CEO: Kazuma Kishida; hereinafter "the Company"),
aiming to develop assisted reproductive technology using oocytes
derived from iPS cells, has raised 7 million
USD. This was achieved through third-party allotment of
shares to six VC and CVC firms, including lead investors Spiral
Capital and Archetype Ventures, existing investor ANRI, a
pharmaceutical company ASKA Pharmaceutical Co., Ltd. and other investors. This funding
will be used to advance research and development and expand the
workforce for global expansion. With this round, the total funds
raised to date amount to approximately 10
million USD.
Investors (in no particular order, titles omitted)
- Spiral Capital Inc.
- Archetype Ventures LLC
- ANRI Inc. (existing investor)
- DG Daiwa Ventures Inc.
- Future Venture Capital Co., Ltd. (ASKA Innovation Fund*1)
- QR Investment Inc. (Hokuriku Regional Venture Fund*2)
- Two individual investors
*1. The Common name for the "ASKA Innovation Investment Limited
Partnership," co-managed by ASKA
Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd.
*2. The Common name for the "Hokuriku Regional Venture
Investment Limited Partnership," co-managed by QR Investment Inc.
(a subsidiary of Hokugin Financial Holdings Inc.) and Carbon
Ventures Inc. (a subsidiary of Mitsutani Sangyo Co., Ltd.)
About the Pipeline
The Company's main pipeline is the provision of a new
infertility treatment using the "DIOLs" technology. This method
involves introducing specific genes into iPS cells to produce
oocytes in a short period, without expensive growth factors or
advanced techniques required by existing production methods,
enabling oocyte production in cheap and large quantities.
Significance of the Technology
Assisted reproductive technology has seen little innovation
since the invention of IVF 45 years ago, and fertility largely
depends on individual conditions and age. Consequently, many women
face life plans based on optimal reproductive age and must choose
between a career or having children. By applying this technology in
assisted reproductive medicine, we aim to free couples from "not
knowing if they can have children" and the constraints of optimal
reproductive age, offering them the choice to become mothers at
their desired time.
Company Overview
- Company Name: Dioseve Inc.
- Headquarters: 1-17-8 Shin-Kiba, Koto-ku, Tokyo Mitsui
Link Lab Shin-Kiba 2, Room 223
- CEO: Kazuma Kishida
- Established: June 30,
2021
- Business: Development of assisted reproductive
technology using oocytes derived from iPS cells
- Website: https://dioseve.com/en/home-en/
View original
content:https://www.prnewswire.com/news-releases/dioseve-completes-funding-round-raising-a-total-of-7-million-usd-302184643.html
SOURCE Dioseve, Inc.